NanoViricides, Inc. (NNVC.PK) to Present at the 2013 Biotechnology Industry Organization (BIO) International Convention in Chicago Today
4/24/2013 7:24:36 AM
More...
|
NanoViricides, Inc. (NNVC.PK) Anticipates FluCide™ Drug Candidates to be Effective Against H7N9
4/22/2013 12:43:32 PM
More...
|
NanoViricides, Inc. (NNVC.PK) President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics and the California NanoSystems Institute at University of California, Los Angeles (UCLA)
3/20/2013 9:35:43 AM
More...
|
NanoViricides, Inc. (NNVC.PK) Announces Retirement of Its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company Reports Having More Than Two Years of Cash on Hand
2/28/2013 10:03:36 AM
More...
|
NanoViricides, Inc. (NNVC.PK) to Present at the 15th Annual Biotechnology Industry Organization (BIO)-CEO Conference in NYC Tomorrow
2/11/2013 6:17:32 AM
More...
|
NanoViricides, Inc. (NNVC.PK) Raises $6 Million From Equity Investors - Reports Having Sufficient Funds for the Initial Human Clinical Trials of its Broad-Spectrum Anti-Influenza Drug
2/4/2013 10:21:33 AM
More...
|
NanoViricides, Inc. (NNVC.PK) Update: FluCide Drug Candidates Significantly Superior to Tamiflu in Animal Studies Against H3N2 and H1N1 Viruses - Company Announces That cGMP Facility Project has Entered Detailed Design Phase
1/15/2013 9:28:29 AM
More...
|
NanoViricides, Inc. (NNVC.PK) Retains AES Clean Technology, Inc. for Design, Engineering and Construction of the Cleanroom Suite in its Previously Announced cGMP Production and Laboratory Facility
1/14/2013 9:01:34 AM
More...
|
NanoViricides, Inc. (NNVC.PK) Appoints Id3A, LLC as Architect for Its Previously Announced cGMP Production and Laboratory Facility
1/2/2013 9:23:48 AM
More...
|
NanoViricides, Inc. (NNVC.PK) Announces Completion of Previously Reported $5 Million in Shelf Offering - Company Reports Having More Than Two Years of Cash on Hand
12/27/2012 9:19:10 AM
More...
|
|